CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function.
PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)-T细胞产品的质量,即记忆和耗竭标志物,影响CAR-T 细胞的长期功能。我们此前报道,piggyBac(PB)转座子介导的CD19 CAR-T 细胞呈现富含记忆表型,其特征是CD45RA+/C-C趋化因子受体7型(CCR7)+T细胞比例较高。为进一步研究PB-CD19 CAR-T 细胞的有利表型,我们从CD45RA+和CD45RA-外周血单个核细胞(PBMC)中生成PB-CD19 CAR-T 细胞(分别为RA+CAR和RA-CAR),并比较其表型和抗肿瘤活性。RA+CAR-T 细胞在转导后24 h显示出更好的瞬时基因转移效率,并且在培养14天后显示出优于RA-CAR-T 细胞的扩增能力。
RA+CAR-T 细胞表现出CD8优势表达、耗竭标志物程序性细胞死亡蛋白-1(PD-1)和T细胞衰老标志物CD57表达降低,以及富集初始/干细胞记忆亚群,这些与CAR-T 细胞的持久性相关。转录组分析显示,即使在抗原刺激后,RA+CAR-T 中经典耗竭标志物也下调。尽管抗原刺激可增加CAR表达,导致强直性CAR信号传导和耗竭,但RA+CAR-T 细胞在抗原刺激后细胞表面CAR分子的表达被控制在相对低于RA-CAR-T 细胞的水平。在体内应激试验中,与RA-CAR-T 细胞相比,RA+CAR-T 细胞实现了延长的肿瘤控制并伴随CAR-T 细胞扩增。在对照组或RA- CAR-T 细胞中未检测到CAR-T 细胞,但RA+ CAR-T 细胞即使在治疗50天后仍扩增,这通过序贯骨髓穿刺得到证实。
我们的结果表明,PB介导的RA+ CAR-T 细胞表现出记忆富集表型和优越的抗肿瘤功能,因此CD45RA+ PBMCs可能被认为是PB-CAR-T 细胞制造的有效起始材料。这种新方法将有利于B细胞恶性肿瘤的有效治疗。
The quality of chimeric antigen receptor (CAR)-T cell products, namely, memory and exhaustion markers, affects the long-term functionality of CAR-T cells.
We previously reported that piggyBac (PB) transposon-mediated CD19 CAR-T cells exhibit a memory-rich phenotype that is characterized by the high proportion of CD45RA + /C-C chemokine receptor type 7 (CCR7) + T-cell fraction. To further investigate the favorable phenotype of PB-CD19 CAR-T cells, we generated PB-CD19 CAR-T cells from CD45RA + and CD45RA - peripheral blood mononuclear cells (PBMCs) (RA + CAR and RA - CAR, respectively), and compared their phenotypes and antitumor activity. RA + CAR-T cells showed better transient gene transfer efficiency 24 h after transduction and superior expansion capacity after 14 days of culture than those shown by RA - CAR-T cells. RA + CAR-T cells exhibited dominant CD8 expression, decreased expression of the exhaustion marker programmed cell death protein-1 (PD-1) and T-cell senescence marker CD57, and enriched na ve/stem cell memory fraction, which are associated with the longevity of CAR-T cells.
Transcriptome analysis showed that canonical exhaustion markers were downregulated in RA + CAR-T, even after antigen stimulation. Although antigen stimulation could increase CAR expression, leading to tonic CAR signaling and exhaustion, the expression of CAR molecules on cell surface after antigen stimulation in RA + CAR-T cells was controlled at a relatively lower level than that in RA - CAR-T cells.
In the in vivo stress test, RA + CAR-T cells achieved prolonged tumor control with expansion of CAR-T cells compared with RA - CAR-T cells. CAR-T cells were not detected in the control or RA - CAR-T cells but RA + CAR-T cells were expanded even after 50 days of treatment, as confirmed by sequential bone marrow aspiration.
Our results suggest that PB-mediated RA + CAR-T cells exhibit a memory-rich phenotype and superior antitumor function, thus CD45RA + PBMCs might be considered an efficient starting material for PB-CAR-T cell manufacturing. This novel approach will be beneficial for effective treatment of B cell malignancies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
READING GUIDES
了解这条资料涉及的技术、疾病或试验登记信息,再回到原始来源核实。
MEMBER ACCOUNT
登录成功会直接打开下一页。